Consun Pharmaceutical Group Limited logo

Consun Pharmaceutical Group Limited

1681.HK

HKSEHealthcareDrug Manufacturers - Specialty & Generic

Latest quote

HK$13.28

−HK$0.32 · -2.35%

Aug 24, 11:59 AM HKT

1681.HK company overview

Regular session · HKT · Market data may be delayed.

Company profile

Company website

Consun Pharmaceutical Group Limited operates as an investment holding company, primarily engaged in the research, development, manufacturing, and distribution of traditional Chinese medicines and sophisticated medical contrast agents throughout the People's Republic of China. The company's operations are structured into two main divisions: Consun Pharmaceutical and Yulin Pharmaceutical. Consun offers a diverse array of pharmaceutical products. For kidney-related conditions, it provides uremic clearance granule for chronic kidney diseases and Yishen Huashi particles to address proteinuria. In the field of medical imaging, the company supplies Gadopentetate Dimeglumine injections, a contrast medium vital for MRI diagnostics of the central nervous system, abdomen, chest, pelvis, and extremities, alongside assessing renal function. Another key imaging agent is Iopamidol injections, utilized in neuroradiology, angiography, and urography. Its extensive portfolio of traditional Chinese medicines includes Zhixueling capsules, effective in managing various bleeding disorders such as uterine bleeding, prolonged lochia, intermenstrual spotting, post-contraceptive ring bleeding, hemorrhoidal bleeding, and epistaxis. Gyn Antidysmenorrheic tablets are offered to alleviate irregular and painful menstruation, including issues experienced during perimenopause due to hepatic depression and blood deficiency. For feminine hygiene, Antibacterial Fujie lotion combats common vaginal infections caused by Staphylococcus aureus, Candida albicans, and Escherichia coli. The company also markets bone-setting liquid and Yunxiang analgesic tincture for a range of ailments including rheumatism, common colds, headaches, stomachaches, chest pain, gastric pain, and chilblains. Additionally, Sanqi Chuangchun capsules are available to enhance blood circulation and reduce stasis, while Shiduqing capsules, tablets, and Paeonol ointment target various skin conditions. The product line is further rounded out with hepatobiliary, gastroenterology, tonic, and other general medicines. Beyond its traditional Chinese remedies and contrast media, the company also markets pharmaceutical products such as Yuanli Kang, an iron-dextrin oral solution; Yibao Yua, an erythromycin estolate suspension; and Yuantong Ning, a cetirizine hydrochloride oral solution. Established in 1997, Consun Pharmaceutical Group Limited is headquartered in Guangzhou, People's Republic of China.

Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
Headquarters
CN
CEO
Meng An
Listed since
Dec 19, 2013
Employees
3,115

Market position

Volume
711K
0.46× average
Average volume
1.55M
Average daily volume
Market cap
11.14B HKD
Beta
0.48
Market reference 1

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
10.95B CNY
P/E (TTM)
8.96×
P/B (TTM)
2.14×
P/S (TTM)
2.79×
EV / EBITDA
9.07×
Earnings yield
8.97%
Free cash flow yield
9.51%
Dividend yield
5.50%

Profitability & efficiency

Gross margin
78.05%
Operating margin
35.18%
Net margin
31.55%
Return on equity
23.76%
Return on assets
16.81%
Return on invested capital
21.08%

Financial health

Debt / equity
0.05×
Current ratio
3.22×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends83%63%44%24%Gross margin, FY2021: 74.70%Gross margin, FY2022: 75.35%Gross margin, FY2023: 74.19%Gross margin, FY2024: 75.56%Gross margin, FY2025: 78.05%Operating margin, FY2021: 34.66%Operating margin, FY2022: 32.37%Operating margin, FY2023: 34.17%Operating margin, FY2024: 35.22%Operating margin, FY2025: 35.18%Net margin, FY2021: 28.86%Net margin, FY2022: 29.19%Net margin, FY2023: 30.29%Net margin, FY2024: 30.68%Net margin, FY2025: 31.55%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 74.70%. Gross margin FY2022 75.35%. Gross margin FY2023 74.19%. Gross margin FY2024 75.56%. Gross margin FY2025 78.05%. Operating margin FY2021 34.66%. Operating margin FY2022 32.37%. Operating margin FY2023 34.17%. Operating margin FY2024 35.22%. Operating margin FY2025 35.18%. Net margin FY2021 28.86%. Net margin FY2022 29.19%. Net margin FY2023 30.29%. Net margin FY2024 30.68%. Net margin FY2025 31.55%.

Income trends

Revenue

3.42B CNY+15.17%

Operating income

1.2B CNY+15.05%

Net income

1.08B CNY+18.41%
Income trends across reported periods3.7B CNY2.57B CNY1.44B CNY307.45M CNYRevenue, FY2021: 2.04B CNYRevenue, FY2022: 2.34B CNYRevenue, FY2023: 2.59B CNYRevenue, FY2024: 2.97B CNYRevenue, FY2025: 3.42B CNYOperating income, FY2021: 708.77M CNYOperating income, FY2022: 757.33M CNYOperating income, FY2023: 884.97M CNYOperating income, FY2024: 1.05B CNYOperating income, FY2025: 1.2B CNYNet income, FY2021: 590.17M CNYNet income, FY2022: 682.91M CNYNet income, FY2023: 784.53M CNYNet income, FY2024: 910.46M CNYNet income, FY2025: 1.08B CNYFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 2.04B CNY. Revenue FY2022 2.34B CNY. Revenue FY2023 2.59B CNY. Revenue FY2024 2.97B CNY. Revenue FY2025 3.42B CNY. Operating income FY2021 708.77M CNY. Operating income FY2022 757.33M CNY. Operating income FY2023 884.97M CNY. Operating income FY2024 1.05B CNY. Operating income FY2025 1.2B CNY. Net income FY2021 590.17M CNY. Net income FY2022 682.91M CNY. Net income FY2023 784.53M CNY. Net income FY2024 910.46M CNY. Net income FY2025 1.08B CNY.
Metric (CNY)FY2025FY2024FY2023FY2022FY2021
Revenue3.42B CNY2.97B CNY2.59B CNY2.34B CNY2.04B CNY
Cost of goods sold750.24M CNY725.13M CNY668.44M CNY576.74M CNY517.32M CNY
Gross profit2.67B CNY2.24B CNY1.92B CNY1.76B CNY1.53B CNY
Research and development151.84M CNY97.54M CNY108.54M CNY117.54M CNY102.16M CNY
Selling, general, and administrative1.52B CNY1.29B CNY1.17B CNY1.09B CNY900M CNY
Operating expenses1.46B CNY1.2B CNY1.04B CNY1.01B CNY818.57M CNY
Interest income85.28M CNY88.3M CNY68.92M CNY52.41M CNY39.25M CNY
Interest expense4.36M CNY24.89M CNY21.26M CNY10.93M CNY12.91M CNY
Depreciation and amortization55.61M CNY71.58M CNY78.09M CNY70.48M CNY68.53M CNY
Operating income1.2B CNY1.05B CNY884.97M CNY757.33M CNY708.77M CNY
Net income1.08B CNY910.46M CNY784.53M CNY682.91M CNY590.17M CNY

Company facts updated Aug 24, 2026.

Earnings

Latest fiscal-year EPS
1.26
FY2025 · +15.60% year over year
Latest fiscal-year revenue
3.42B CNY
FY2025 · +15.17% year over year

Annual EPS trend

Reported history and fiscal-year consensus

ReportedConsensus forecast
Annual EPS trend1.311.10.890.68FY21FY22FY23FY24FY25

Annual revenue trend

Reported history and fiscal-year consensus

ReportedConsensus forecast
Annual revenue trend3.55B3.01B2.46B1.91BFY21FY22FY23FY24FY25

Corporate actions

Annual dividends per share

Cash distributions grouped by calendar year; partial years are marked.

HK$0.63

2025 complete year+250.0% since 2020

2026 partial: HK$0.40

* Partial calendar year in the available dividend history.

Corporate action history

Dividend

Ex-dividend Jun 9, 2026

HK$0.40

Semi-Annual

Record Jun 10, 2026 · Payment Jun 22, 2026

Dividend

Ex-dividend Sep 4, 2025

HK$0.33

Semi-Annual

Record Sep 5, 2025 · Payment Sep 19, 2025

Dividend

Ex-dividend Jun 10, 2025

HK$0.30

Semi-Annual

Record Jun 11, 2025 · Payment Jun 20, 2025

Dividend

Ex-dividend Sep 5, 2024

HK$0.30

Annual

Record Sep 9, 2024 · Payment Sep 20, 2024

Dividend

Ex-dividend Jun 11, 2024

HK$0.60

Special

Record Jun 12, 2024 · Payment Jun 21, 2024

Dividend

Ex-dividend Sep 7, 2023

HK$0.15

Quarterly

Record Sep 11, 2023 · Payment Sep 20, 2023

1681.HK peers

ETFs holding 1681.HK

Funds reporting this stock among their holdings, ordered by reported position size.

Continue in GoAI

Research 1681.HK

research.disclaimer